Ovarian Epithelial Carcinoma clinical trials at UCSD
1 research study open to eligible people
Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery
open to eligible females ages 18 years and up
Study to compare the safety and efficacy of oregovomab versus placebo, administered in combination with specific cycles of a standard six-cycle chemotherapy regimen (paclitaxel and carboplatin), for the treatment of subjects with newly diagnosed advanced ovarian cancer who have undergone optimal debulking.
La Jolla, California and other locations
Our lead scientists for Ovarian Epithelial Carcinoma research studies include Ramez Eskander, MD.